Tyrosine kinase inhibitorFDA-approvedSecond-line
Tagrisso
Generic name: osimertinib
How it works
Blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— EGFR-mutated
Efficacy
Studies show that patients with EGFR-mutated non-small cell lung cancer who received Tagrisso had a response rate of approximately 70%.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Cancer Treatment Models for Lung Cancer Patients | Lung Cancer | phase-3 | — | Source → |
| Improving Osimertinib Resistance in Lung Cancer Cells | Lung Cancer | lab-study | — | Source → |
| Sequential Afatinib and Osimertinib Therapy Shows Promise in Lung Cancer | Lung Cancer | observational | Sequential afatinib-osimertinib therapy achieved a median OS of 55 months compared to 32.3 months with alternative strategies. | Source → |
| Combining Osimertinib and Brain Radiation for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Combining two cancer drugs may improve lung cancer treatment | Lung Cancer | phase-3 | The combination nearly doubled progression-free survival (PFS) compared with chemotherapy (9.8 vs. 5.4 months; hazard ratio 0.34) | Source → |
| Combining Osimertinib with AKR1C3 Inhibitor May Help Overcome Lung Cancer Resistance | Lung Cancer | lab-study | — | Source → |
| Osimertinib with or without Chemotherapy in Lung Cancer Patients | Lung Cancer | phase-3 | Combining osimertinib with chemotherapy improved progression-free survival versus osimertinib alone (HR, 0.62; P < 0.001). | Source → |
| Osimertinib Linked to Increased Heart Risks | Lung Cancer | meta-analysis | — | Source → |
| Osimertinib Resistance in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Understanding Resistance to Osimertinib in Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Cancer Cells May Use Special Structures to Resist Treatment | Lung Cancer | lab-study | — | Source → |
| Osimertinib May Help Some Lung Cancer Patients with Specific Mutation | Lung Cancer | observational | The patient achieved a progression-free survival of 10 months. | Source → |
| Osimertinib Resistance in Lung Cancer: A New Signaling Pathway Identified | Lung Cancer | lab-study | — | Source → |
| Rare Lung Cancer Mutation Responds to Afatinib and Osimertinib | Lung Cancer | observational | — | Source → |
| Researchers Explore Ways to Overcome Resistance to Osimertinib in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Osimertinib Effective for Lung Cancer Patients with EGFR Mutation | Lung Cancer | meta-analysis | Osimertinib demonstrated significantly superior objective response rate (ORR) compared to control treatments (relative risk [RR] = 1.59, 95% confidence interval [CI] = 1.16 to 2.17, p < .001), exceeding the minimal clinically important difference threshold. | Source → |
| Osimertinib and Chemotherapy Combination Shows Promise in Lung Cancer | Lung Cancer | phase-3 | The experimental group demonstrated longer median progression-free survival (15.7 vs 10.6 months) and overall survival (24.6 vs 17.5 months) compared to the control group. | Source → |
| Genetic Changes in Lung Cancer Patients Predict Treatment Outcomes | Lung Cancer | observational | Patients with mutations in exon 5 had a hazard ratio of 7.67 for reduced treatment period and 9.29 for overall survival compared to wild-type patients. | Source → |
| New Study Examines Osimertinib Effectiveness in Lung Cancer Patients | Lung Cancer | phase-2 | The objective response rate was 61.8%, and grade 3 or higher adverse events occurred in 22.1% of the patients. | Source → |
| Eugenol May Help Overcome Lung Cancer Resistance to Osimertinib | Lung Cancer | lab-study | — | Source → |
| PD-L1 Expression May Affect Osimertinib Outcomes in Lung Cancer | Lung Cancer | meta-analysis | Higher PD-L1 expression (≥50%) was associated with a 3.03-fold increased risk of progression or death. | Source → |
| Researchers Find New Way to Overcome Osimertinib Resistance in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Osimertinib Monotherapy for Advanced Lung Cancer with Atypical EGFR Mutations | Lung Cancer | observational | Median progression-free survival was 8.8 months, and median overall survival was 28.5 months overall, 42.5 months in patients with compound EGFR mutations, and 20.0 months in those with atypical mutations alone. | Source → |
| Gene Amplification Linked to Osimertinib Efficacy in Lung Cancer | Lung Cancer | observational | Overall survival was significantly shorter for actinin-4 immunohistochemistry-positive patients than for actinin-4 immunohistochemistry-negative patients (hazard ratio, 2.76; 95% confidence interval, 1.02-7.45). | Source → |
| Understanding Drug-Tolerant Cancer Cells in Lung Cancer | Lung Cancer | lab-study | Notably, this strategy showed superior efficacy compared with osimertinib combinations with chemotherapy or AXL inhibitor in both settings. | Source → |
| PD-L1's Role in Lung Cancer Resistance to Osimertinib | Lung Cancer | lab-study | — | Source → |
| New Cancer Compound Shows Promise in Lung Cancer Research | Lung Cancer | lab-study | Compound 14l achieved the lowest IC₅₀ values and strong EGFR kinase inhibition (IC₅₀ = 50.58 ± 3.87 nM). | Source → |
| New Compound May Help Overcome Lung Cancer Resistance to Osimertinib | Lung Cancer | lab-study | — | Source → |
| Osimertinib Effective in Advanced Lung Cancer Patients | Lung Cancer | observational | The median progression-free survival was 15.8 months, and the median overall survival was 29.3 months. | Source → |
| Understanding Resistance to Osimertinib in Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Osimertinib as First-Line Treatment for Lung Cancer | Lung Cancer | observational | The median first-line progression-free survival was 19.0 months in the osimertinib group. | Source → |
| PET Scans May Help Predict Lung Cancer Treatment Outcomes | Lung Cancer | observational | — | Source → |
| T cell immunity may slow down lung cancer resistance to treatment | Lung Cancer | observational | Patients with higher CXCR3CCR4CCR6CD4 T cell levels exhibited significantly enhanced PFS (p = 0.002) and OS (p = 0.0006). | Source → |
| New Study Compares Cancer Treatments for Lung Cancer Patients | Lung Cancer | meta-analysis | Osimertinib resulted in significantly longer overall survival compared to erlotinib-based regimens (HR for OS vs. erlotinib: 1.59, 95% CI 1.09-2.31). | Source → |
| Radiation Therapy Extends Time on Osimertinib for Some Lung Cancer Patients | Lung Cancer | observational | After XRT, time on osimertinib was extended for a median of 9.7 months, with a median progression-free survival (PFS) and overall survival of 6.9 and 24.4 months, respectively. | Source → |
| Understanding Resistance to Lung Cancer Drugs | Lung Cancer | lab-study | — | Source → |
| Osimertinib Effective in Treating Lung Cancer with Brain Metastases | Lung Cancer | observational | The CNS-ORR was 91.9% and the CNS-DCR was 100%. | Source → |
| Rare Side Effect of Osimertinib in Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| Rare Blood Disorder Linked to Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.